Author Question: A 43-year-old male who is 510 tall and weighs 216 lb has been informed by his nurse practitioner ... (Read 62 times)

faduma · **on:** Jun 25, 2018

A 43-year-old male who is 510 tall and weighs 216 lb has been informed by his nurse practitioner that his body mass index (BMI) is 31.

Which of the following clinical conclusions based on these data would his nurse be most justified in rejecting?
A)
Further investigation of his nutritional status is needed to supplement the BMI value.
B)
The client faces an increased risk of type 2 diabetes and hyperlipidemia.
C)
He is classified as being obese, likely as the result of the interplay of genetic and lifestyle factors.
D)
The client is borderline obese but is not yet at the point of significantly increased risks to health.

Question 2

A male patient comes to the clinic asking to speak to a health care provider privately. He reveals that he had shared a needle/syringe with a prostitute (shooting up cocaine) and then had unprotected sex.

Upon questioning, it was revealed that the patient had not had any immunization for hepatitis B. Which of the following medications would the nurse anticipate administering today to this patient?
A)
Tenofovir disoproxil fumarate plus emtricitabine
B)
Hepatitis B immunoglobulin (HBIG)
C)
Hepatitis C immunoglobulin (HCIG)
D)
Hepatitis A vaccine

wuly · **Reply #1 on:** Jun 25, 2018

Answer to Question 1

Ans:
D

Feedback:

A BMI of 31 is classified as obese, and the client faces a risk of hypertension, hyperlipidemia, type 2 diabetes, coronary heart disease, and other health problems. While BMI is a valid instrument, other data sources are needed to supplement this value clinically. Obesity is considered to be an outcome of a variety of factors including heredity and lifestyle.

Answer to Question 2

Ans:
B

Feedback:

HBIG is used as an adjunct to hepatitis B vaccine for postexposure immunoprophylaxis to prevent HBV infections in high-risk populations. Tenofovir disoproxil fumarate plus emtricitabine is for HIV preexposure coverage. There is no hepatitis C vaccine available on the market yet. Hepatitis A vaccine is for HAV, which is usually spread from fecal-oral routes.